Comparison · NCT00891930-sae
Part 1 Panitumumab + Irinotecan vs Part 2 Panitumumab + AMG479: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Part 1 Panitumumab + Irinotecan vs Part 2 Panitumumab + AMG479: serious adverse events. Trial comparisons, record NCT00891930-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00891930-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.351 | 0.252 | 0.465 | wilson | |
| Risk in group 2 | 0.222 | 0.117 | 0.381 | wilson | |
| Risk difference, group 1 minus group 2 | 0.129 | -0.0578 | 0.284 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.58 | 0.797 | 3.14 | log | |
| Odds ratio, group 1 over group 2 | 1.9 | 0.756 | 4.75 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Part 1 Panitumumab + Irinotecan than on Part 2 Panitumumab + AMG479 | 7.74 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Part 1 Panitumumab + Irinotecan | open label panitumumab 6 mg/kg every 2 weeks plus irinotecan 180 mg/m2 every 2 weeks | 26 | 74 | EG000 |
| Group 2 | Part 2 Panitumumab + AMG479 | treatment with panitumumab 6 mg/kg every 2 weeks plus AMG 479 12 mg/kg every 2 weeks. | 8 | 36 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Part 1: All-Cause Mortality was assessed up to 152 weeks and all other adverse events were collected up to 79 weeks; Part 2: All-Cause Mortality was assessed from start of part 2 up to 119 weeks from time of randomization and all other adverse events were collected up to 41 weeks from time of randomization.
Source ClinicalTrials.gov
Trial
- Title
- Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
- NCT number
- NCT00891930
- Phases
- PHASE2
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Panitumumab, Ganitumab, Irinotecan
- Lead sponsor
- NantBioScience, Inc.
- Results first posted
- 2016-02-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00891930?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00891930-sae